Session Title: Quick Fire Free Paper 4
Session Date/Time: Sunday 14/09/2014 | 08:00-10:00
Paper Time: 08:45
Venue: Boulevard B
First Author: : L.Tulasiram INDIA
Co Author(s): : P. Puttaiah J. Prasanna
To know the effect of intravitreal Ranibizumab in cases of circumscribed choroidal haemangioma.
6 cases of clinically suspected circumscribed choroidal haemangiomas underwent fundus fluorescein angiography (FFA), optical coherence tomography (OCT), Indocyanine green angiography (ICG) and B-scan at the base hospital.
Patients presenting with long standing unexplained visual loss and on clinical examination found to have an elevated, orange-red lesion in the macula, diagnosed as circumscribed choroidal haemangioma by FFA, OCT, ICG and B-scan were included for the study. Intraocular lesions such as amelanotic melanomas, metastatic tumors of the eye, choroidal osteomas, disciform scar, serous retinal detachment and central serous retinopathy (CSR) were excluded. All patients underwent a standard intravitreal injection of 0.05ml Ranibizumab under aseptic precautions in the operation theatre.
Significant reduction in the size of the tumour was noticed in 5 out of 6 cases (p<0.5) over a period of 6-12 weeks and maintained through 48 weeks of follow up. There was an improvement in the visual acuity by upto 1.5 lines in 4 of the 6 cases. One case showed worsening of the visual acuity with no changes in the size of the lesion till last follow up. There was a transient raise in the intra ocular pressure in one case which settled with anti-glaucoma medication.
Our study shows that a single dose of Ranibizumab works effectively in cases of circumscribed choroidal haemangiomas with minimal side effects and risk factors, when compared to other modalities of treatment.